Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADMIRAL study of multiple ascending doses of STK-001 in pediatric Dravet syndrome
ISRCTN99651026Phase 2Completed
- Sponsor
- Stoke Therapeutics
- Start
- Jul 2021
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 2, open-label trial of zorevunersen in Dravet syndrome (3 cohorts), sponsored by Stoke Therapeutics. Primary endpoints: Safety and tolerability, Plasma pharmacokinetics of STK-001 and 1 more. Started Jul 2021; status: completed.
02
Drugs
zorevunersen
03
Conditions
Dravet syndrome
Beyond the preview
Go deeper on ISRCTN99651026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99651026.